All PlansCoverageHigh impact
Recall: Quinapril
UPMC Health Plan·PA · Cardiology, Internal Medicine, Family Medicine +3 more·Pharmacy
We identified it
Aug 7, 2026
Summary
Lupin Pharmaceuticals has recalled four lots of Quinapril Tablets due to nitrosamine impurity (N-Nitroso-Quinapril) levels exceeding acceptable daily intake limits, which may increase cancer risk with long-term exposure. The billing team must identify affected patients on this medication and coordinate with providers and pharmacy to ensure medication switches and appropriate documentation.
Action Required
Immediately: Billing and clinical teams must identify all patients currently prescribed Quinapril Tablets from the recalled lots. Coordinate with prescribing providers to switch affected patients to alternative ACE inhibitors and document the medication change in the EHR. Update any pending claims or authorizations related to Quinapril to reflect the new medication. Notify patients of the recall through the patient portal or direct communication per provider protocol. Monitor for any additional guidance from UPMCHealthPlan regarding coverage of replacement medications or related claims adjustments. Document all recall-related actions in patient records for compliance purposes.